.jetcityimage/iStock Content via Getty Images Morgan Stanley has decided on Eli Lilly (NYSE: LLY) as its own top biopharma pick for 2025 and also measured one more 9 titles in the area as obese. The investment financial institution stated in a note that it remains to feel “diabesity is actually set to come to be.